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CObjectives: To map Functional Assessment of Cancer Therapy-Gen-
eral (FACT-G) and Functional Assessment of Cancer Therapy-Colorec-
tal (FACT-C) subscale scores onto six-dimensional health state short
form (derived from short form 36 health survey) (SF-6D) preference-
based values in patients with colorectal neoplasm, with and without
adjustment for clinical and demographic characteristics. These results
can then be applied to studies that have used FACT-G or FACT-C
to predict SF-6D utility values to inform economic evaluation.
Methods: Ordinary least square regressions were estimated mapping
FACT-G and FACT-C onto SF-6D by using cross-sectional data of 537
Chinese subjects with different stages of colorectal neoplasm. Mapping
functions for SF-6D preference-based values were developed sepa-
rately for FACT-G and FACT-C in four sequential models for addition of
variables: 1) main-effect terms, 2) squared terms, 3) interaction terms,
and 4) clinical and demographic variables. Predictive performance in
each model was assessed by the R2, adjusted R2, predicted R2, informa-
tion criteria (Akaike information criteria and Bayesian information cri-
teria), the root mean square error, the mean absolute error, and the
proportions of absolute error within the threshold of 0.05 and 0.10. O
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oi:10.1016/j.jval.2011.12.009Results: Models including FACT variables and clinical and demo-
graphic variables had the best predictive performance measured by
using R2 (FACT-G: 59.98%; FACT-C: 60.43%), root mean square error
FACT-G: 0.086; FACT-C: 0.084), and mean absolute error (FACT-G:
.065; FACT-C: 0.065). The FACT-C–based mapping function had better
redictive ability than did the FACT-G–based mapping function.
onclusions: Models mapping FACT-G and FACT-C onto SF-6D
eached an acceptable degree of precision. Mapping from the condi-
ion-specific measure (FACT-C) had better performance than did map-
ing from the general cancer measure (FACT-G). These mapping func-
ions can be applied to FACT-G or FACT-C data sets to estimate SF-6D
tility values for economic evaluation of medical interventions for pa-
ients with colorectal neoplasm. Further research assessing model per-
ormance in independent data sets and non-Chinese populations are
ncouraged.
eywords: colorectal neoplasm, FACT-C, mapping, patient-reported
utcomes, quality of life, SF-6D.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Colorectal neoplasm (CRN) is becoming a leading burden of dis-
ease worldwide [1]. More advanced clinical interventions includ-
ing screening and chemotherapeutic treatment have been devel-
oped for CRN, but most of them are costly. Economic evaluation
using cost-effectiveness analysis is commonly used to appraise
clinical interventions to inform resource allocation. Quality-ad-
justed life-years are used as a general measure of health effects to
capture both morbidity and mortality [2]. The “Q” quality adjust-
ment weight of the quality-adjusted life-year, ranging from 0 for
death to 1 for perfect health, is calculated by using a preference-
* Address correspondence to: Carlos K.H. Wong, Department of Fa
ei Chau Clinic, 161 Ap Lei Chau Main Street, Ap Lei Chau, Hong K
E-mail: carlosho@hku.hk.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.based valuation of health elicited by direct or indirect methods [3].
Direct valuation techniques, such as standard gamble or time
trade-off of colorectal cancer (CRC) health states [4], can be used to
elicit utility values from patients for their own health, but its va-
lidity is questioned [5,6] on the grounds that utility should be
judged by society as a whole. An alternative method is the use of
preference-based measures that have been valued by the general
population, for example, the EuroQol five-dimensional (EQ-5D)
questionnaire [7] and the six-dimensional health state short form
derived from short form 36 health survey (SF-6D) [8,9]. The EQ-5D
uestionnaire is recommended by the National Institute of Health
nd Clinical Excellence [2] and is widely used in Europe. The SF-6D
Medicine and Primary Care, The University of Hong Kong, 3/F, Ap
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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496 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 3derived from health states measured by Medical Outcomes Study
SF-36 Health Survey [8] is more popular in the United States and
sia. Population-specific scoring algorithms for SF-6D are avail-
ble for the United Kingdom [8,9], Japan [10], Portugal [11], Hong
ong [12], and Brazil [13].
Condition-specific health-related quality-of-life (HRQOL) mea-
ures are usually not preference based. “Mapping” the generic or
ondition-specific HRQOL measures onto generic preference-
ased measures is a method that can be used to predict utility
alues even though the preference-based measure was not in-
luded in the study. Mapping involves two stages. First, regression
nalysis is used to estimate the relationship between the “source”
on–preference-based measure and the “target” preference-based
easure. Second, this relationship can be applied to a study data
et containing the source measure to predict. In recent years, nu-
erous studies have successfully developed functions mapping
rom non–preference-based instruments onto EQ-5D question-
aire and SF-6D preference-based values in different patient
roups [14–16]; see Brazier et al. [17] for a recent overview. Most
tudies in the literature have mapped onto the EQ-5D question-
aire [17]. Yet studies mapping onto both the EQ-5D questionnaire
nd SF-6D found that the models mapping onto SF-6D had better
redictive performance than did those mapping onto the EQ-5D
uestionnaire [14,15].
The Functional Assessment of Cancer Therapy-Colorectal
FACT-C) is a popular HRQOL measure specific for CRN. Its psycho-
etric properties were tested and confirmed in Chinese patients
ith colorectal polyps or cancer [18]. The FACT-C is an extended
ersion of the FACT-General (FACT-G), which makes up four of the
ve subscales of the former. Mappings from FACT-G or FACT-C
nto SF-6D provide a useful function for converting profile HRQOL
cores collected by these condition-specific measures commonly
sed in cancer clinical trials to preference-based values for the
alculation of quality-adjusted life-years for cost-effectiveness
nalysis.
Mapping studies often incorporate demographic and clinical
haracteristics into model estimation to increase a model’s pre-
ictive performance [16,19–21]. Demographics (age and gender)
nd tumor stage of CRN variables were included in the analysis.
he aim of this study was to map from FACT-G and FACT-C sub-
cale scores to SF-6D preference-based values in patients with
RN, with and without adjustment for clinical and demographic
haracteristics. The mapping function allowed researchers to con-
uct health economic appraisals of preventive screening and
reatment program for CRN.
Methods
Subjects
All Chinese patients 18 years or older with a histology of confirmed
colorectal polyp or cancer for at least 6 months were recruited
from specialist outpatient medical and surgical colorectal clinics
of a regional hospital in Hong Kong between October 2009 and
September 2010. Patients were excluded if the doctor judged their
life expectancy to be less than 6 months; they were unable to
communicate in Cantonese; they had a known cognitive impair-
ment; or they were too ill to participate in an interview. A total of
575 patients were invited to participate and of these 20 were un-
reachable and 2 withdrew, meaning 553 subjects were success-
fully interviewed via telephone (449 subjects) or face to face (104
subjects) by trained interviewers. Clinical characteristics such as
tumor stage, treatment status, and colostomy status were re-
trieved from the medical records of patients. The CRN was classi-
fied into six stages on the basis of screening surveillance guideline
[22] and American Joint Committee on Cancer (AJCC) staging sys-
tem [23]: 1) low-risk polyps group (patients with 2 adenomas or3–4 adenomas all of which were not larger than 1 cm), 2) high-risk
polyps group (patients with5 adenomas or with3 adenomas at
least one of which was larger than 1 cm), 3) stage I CRC, 4) stage II
CRC, 5) stage III CRC, and 6) stage IV CRC. The tumor stage of CRN
was classified as unknown if it was not specified in the medical
record. Demographic and clinical characteristics of the patients
are presented in Table 1. Patients had an average age of 63.2 years
(SD: 11.3) and 42.0% were females. For the stage of CRN, the mode
was “stage III” with a percentage of 20.6%; the proportions of the
other stages ranged from 13.0% to 18.3%. Among all patients, eight
subjects (1.4%) had unknown stage of diagnosis and were excluded
before the regression analysis of the mapping functions of SF-6D.
Data collection
Preference-based value and condition-specific HRQOL data were
collected by using the Hong Kong Chinese version of SF-6D and
traditional Chinese (Hong Kong) FACT-C Version 4, respectively.
These instruments were administrated by trained interviewers at
the same time. Clinical data were obtained from the doctors or
extracted from the medical records of patients [24]. This study was
approved by institutional review boards at the University of Hong
Kong and Hospital Authority Hong Kong West Cluster (IRB Ref#
UW 09-391).
Study instruments
FACT-G, developed by the Center on Outcomes, Research and Ed-
ucation [25], is widely used to measure HRQOL for cancer patients
in clinical trials. It is the core member of FACT instruments includ-
ing four subscales: 1) 7-item physical well-being (PWB), 2) 7-item
social/family well-being (SWB), 3) 6-item emotional well-being
(EWB), and 4) 7-item functional well-being (FWB). FACT-C (Version
4) is the CRC-specific member of FACT instruments that includes
the four FACT-G subscales plus a 9-item colorectal cancer subscale
(CCS) that addresses additional concerns on quality of life for CRC
[26]. All items have five response options (“not at all,” “a little bit,”
”somewhat,” “quite a bit,” and “very much”). Each domain has a
subscale score where higher scores indicate better HRQOL. Both
FACT-G and FACT-C are designed for either patient self-comple-
Table 1 – Sociodemographic and clinical characteristics
of study subjects.
Total (n  553)
Age (y), mean  SD 63.2  11.3
Sex, n (%)
Male 321 (58.0)
Female 232 (42.0)
Stage of colorectal neoplasm, n (%)
Low-risk polyp 93 (16.8)
High-risk polyp 72 (13.0)
Stage I 83 (15.0)
Stage II 101 (18.3)
Stage III 114 (20.6)
Stage IV 82 (14.8)
Unknown 8 (1.4)
Duration of diagnosis (mo), mean  SD 46.6  55.8
Treatment status, n (%)*
Palliative 63 (16.4)
Adjuvant 26 (6.8)
No 296 (76.9)
Stoma (%)*
Yes 51 (13.2)
No 334 (86.8)
* Colorectal cancer patients only (n  385).tion [25] or interviewer administration [18,27]. They can be admin-
i
g
s
e
H
s
a
t
f
c
r
o
n
a
o
f
s
b
497V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 3istered face to face or on telephone by trained interviewers [25].
The traditional Chinese version of FACT-C has been shown to be
valid and reliable in Chinese patients with colorectal polyps or
CRC in Hong Kong [18].
The SF-6D is a preference-based measure of health consisting
of six aspects of health dimensions—physical functioning, role
limitations, social functioning, pain, mental health, and vitality;
each dimension is classified into four to six levels, giving a total of
18,000 combinations of health states. The SF-6D was originally
developed by Brazier et al.[8]. It was translated into the Hong Kong
Chinese version by Lam et al. [12], which was validated and valued
n the Hong Kong general Chinese population by using standard
amble [12,28]. The Hong Kong population-specific preference
coring algorithm was used in this study here because these pref-
rences are most representative of this patient population. The
ong Kong Chinese version of the SF-6D can be administrated by
elf or an interviewer [29]. Telephonic interview was acceptable to
dminister SF-6D because our preliminary analysis showed that
he SF-6D values difference between telephone (449 subjects) and
ace-to-face (104 subjects) interviews was not statistically signifi-
ant (P  0.152) by nonparametric Mann-Whitney U test.
Statistical analysis
Model specification
Model specification was informed by prior descriptive analysis of all
variables. Separate models were estimated by mapping FACT-C and
FACT-G onto SF-6D. Models were estimated by using 1) FACT vari-
ables using main effects, 2) as per point 1 plus squared terms, 3) as
per point 1 plus interaction terms, and 4) as per point 3 plus clinical
and demographics variables. Additional variables were added by us-
ing the stepwise regression technique. Ordinary least square method
was used for all analysis. The F test was used to retain variables with
an inclusion criterion of P value lower than 0.05 and exclusion crite-
ion of P value greater than 0.10. Lower-order main effect terms (first
rder) were retained in the model even if their effects became insig-
ificant when squared and interaction terms (second order) were
dded because of the principle of hierarchy. To ensure comparability
f different models, only subjects with complete data (n537) across
all variables were used in the analysis.
Model comparison
R2 and the adjusted R2 (Adj R2) statistics were used to measure the
explanatory power of each model, that is, how much of the vari-
ability in the dependent variable was explained by the predictors.
In addition, predicted R2 (Pred R2) was calculated by one minus a
raction of predicted residual sum of squares over total sum of
Table 2 – Descriptive statistics for SF-6D preference-based
Mean  SD 95% CI
Preference-based values
SF-6D 0.825  0.136 0.813–0.836
FACT-C subscale
PWB 25.69  3.25 25.41–25.96
SWB 19.89  4.36 19.52–20.26
EWB 21.34  2.90 21.09–21.58
FWB 18.92  4.38 18.55–19.29
CCS 21.74  3.14 21.47–22.00
Note. PWB, SWB, EWB, and FWB form the FACT-G.
CCS, colorectal cancer subscale; CI, confidence interval; EWB, emo
Colorectal; FACT-G, Functional Assessment of Cancer Therapy-Gen
dimensional health state short form (derived from short form 36 health suquares, which is more able than R2 to assess the performance of a
model for predicting new observations [30]. Of prime importance
for selecting between models is predictive performance. Models
with low errors are preferred because this implies that the model
will have better predictive performance when used in other data
sets to predict SF-6D. To assess the predictive ability of a model,
the differences between the predicted and observed SF-6D values
at the individual level were examined by computing the root mean
square error (RMSE) and the mean absolute error (MAE). In addi-
tion, the number of observations and the corresponding propor-
tions in the full sample that the absolute error (AE) was greater
than the threshold of 0.05 and 0.10 for each individual were calcu-
lated, respectively. The goodness of fit of the model was described
by using Akaike information criteria and Bayesian information crite-
ria statistic. The achievable ranges of the SF-6D preference-based
values from the resulting mapping functions were compared with
the observed range of the SF-6D values. Residual plots for the final
models were used as the primary tool to examine model adequacy
such as the non-normality and heteroscedasticity.
Model validation
The validity and robustness of the mapping functions were as-
sessed by using the 10-fold cross-validation procedure [20]. The
full sample was randomly split into 10 equally sized groups. Each
combination of nine groups formed a training data set that was
used to estimate the parameters of the regression model, while
the remaining group was considered as a test data set that exam-
ined the errors of prediction of the model generated by the training
data set. The test data set was validated by inputting the indepen-
dent variables of each observation of the test data set into the
model fitted by the training data set. Differences of the observed
value of the dependent variable from the predicted value calcu-
lated from the model were the error of prediction. The above pro-
cedure was repeated until all the 10 possible training data sets
were tested. The errors of prediction for all observations were ob-
tained to calculate the RMSE, MAE, and percentages of AEs greater
than 0.05 and 0.10 (AE  0.05 and AE  0.10).
All regressions and other statistical analyses were conducted
y using the SPSS, Version 18.0 (SPSS, IBM, Inc., Chicago, IL).
Results
Descriptive statistics for SF-6D and FACT-C
Observed SF-6D and FACT-C/FACT-G subscale scores of the sub-
jects are shown in Table 2. The mean score of SF-6D was 0.825 (SD:
es and FACT-C subscale scores.
%Floor %Ceiling Observed
range
Theoretical
range
0.00 4.28 0.385–1.00 0.315–1.00
0.00 40.22 4–28 0–28
0.37 3.72 0–28 0–28
0.00 9.87 9–24 0–24
0.00 2.61 1–28 0–28
0.00 2.05 9–28 0–28
l well-being; FACT-C, Functional Assessment of Cancer Therapy-
FWB, functional well-being; PWB, physical well-being; SF-6D, six-valu
tiona
eral;rvey); SWB, social/family well-being.
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498 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 30.136, 95% confidence interval: 0.813–0.836), ranging from 0.385 to
1, which was narrower than the theoretical range of 0.315 to 1
based on Hong Kong data [28]. There was no floor effect in mea-
suring the SF-6D score in the sample while a slight ceiling effect
was observed, with 4.28% of patients having the best possible level
of health state value of 1. There were no floor effects observed in
the subscales except a very small one in SWB (0.37%). Ceiling ef-
fects were observed in all FACT-C subscales, with the highest
found in PWB (40.22%).
Regression modeling of the FACT-G–based mapping function
Table 3 shows the results of the analyses with FACT-G subscales
scores. The main-effect terms selected from the FACT-G subscale
scores in the first model (model G1) were PWB, EWB, and FWB. All
the squared terms of PWB, EWB, and FWB scores were included in
the second model (model G2) whereas their no interaction
terms were significant (model not shown). Tumor stage and sex
were eventually added to the model in the last model (model
G3). Although PWB, EWB, and FWB contributed significantly in
the first model (model G1), the effects of the main-effect terms
of EWB and FWB became insignificant after the squared terms
were added in the second model (model G2). Sex but not age was
significant in the final model (model G3). The effects of tumor
stage were significant except the subgroup effect of “high-risk
polyps.” The final model had a R2 of 59.98%, an Adj R2 of 59.07%,
nd a Pred R2 of 57.22%. RMSE and MAE were 0.086 and 0.067,
Table 3 – Prediction models for patients with colorectal neo
clinical and demographical variables.
Main effects (G1) Sq
Coefficient 95% CI Coeffi
PWB 0.01770* (0.01469,0.02071) 0.
EWB 0.00446* (0.00119,0.00773) 0.
FWB 0.01128* (0.00917,0.01338) 0.
PWB2 0.
EWB2 0.
FWB2 0.
Stage†
Low risk
High risk
Stage I
Stage II
Stage III
Female
Constant 0.06169 (0.00643,0.12981) 0.
R2 54.95% 58
Adj R2 54.70% 58
Pred R2 53.74% 56
AIC 1041.27 1080.
BIC 1019.84 1045.
RMSE 0.091 0.
MAE 0.070 0.
AE  0.05 300 (55.87%)
AE  0.10 122 (22.72%)
Range of fitted 0.299–0.980
Adj R2, adjusted R2; AE, absolute error; AIC, Akaike information criter
values; EWB, emotional well-being; FACT-G, Functional Assessment o
lute error; Pred R2, predicted R2; PWB, physical well-being; RMSE, roo
* Significant with P  0.05.
† Stage IV is the reference category of colorectal neoplasm staging.respectively. The percentage of AE greater than 0.05 was 51.58%while that of AE greater than 0.10 was 23.84%. The fitted range of
the SF-6D preference-based values estimated for the mapping
function was 0.491 to 1.038, the lower bound of which was 0.11
more than that of the observed SF-6D range (0.385–1). The scat-
ter plot of mean observed and predicted SF-6D preference-
based values by the health state ranking in descending order of
the mean observed values (Table 5 and Fig. 1) indicates overpre-
iction for more severe health states, where observed SF-6D
alue was less than 0.8.
The performance of model G2 without the demographic and
linical variables was only slightly inferior to that of the final
odel, with an adjustedR2 of 58.1%, and favorable RMSE, MAE, and
AE proportions.
Regression modeling of the FACT-C–based mapping function
Mapping function of FACT-C subscales scores is shown in Table 4.
Similar to the model for FACT-G, PWB, EWB, and FWB scores were
selected as the main-effect terms in first model (model C1) to
which was added the CCS. Among the four squared terms, PWB2
and EWB2 entered the model in the second model (model C2).
EWB2, however, was removed from the model in the third model
(model C3) that integrated the interaction terms of PWB  FWB,
WB  CCS, and FWB  CCS. In the final model (model C4), tumor
effects of “high-risk polyps,” “stage I CRC,” and “stage III CRC”
were insignificant. The final model achieved a R2 of 61.65%, an
Adj R2 of 60.63%, a Pred R2 of 58.41%, and the smallest Akaike
m using main effects, squared terms of FACT-G, and
-G–based model
d terms added (G2) Clinical and demographical
variables added (G3)
95% CI Coefficient 95% CI
* (0.04265,0.00787) 0.02705* (0.04434,0.00976)
(0.05149,0.00270) 0.02356 (0.05052,0.00339)
(0.00485,0.01033) 0.00324 (0.00431,0.01078)
* (0.00061,0.00139) 0.00102* (0.00063,0.00140)
* (0.00004,0.00147) 0.00072* (0.00001,0.00143)
* (0.00003,0.00045) 0.00023* (0.00001,0.00044)
0.04238* (0.01528,0.06947)
0.01294 (0.01574,0.04163)
0.02808* (0.00031,0.05586)
0.03908* (0.01254,0.06562)
0.02692* (0.00133,0.05251)
0.01963* (0.03523,0.00403)
* (0.55594,1.10390) 0.84470* (0.57168,1.11771)
59.98%
59.07%
57.22%
1086.87
1026.87
0.086
0.067
296 (55.12%) 277 (51.58%)
122 (22.72%) 128 (23.84%)
0.490–1.023 0.491–1.038
C, Bayesian information criteria; CI, confidence interval; fitted, fitted
cer Therapy-General; FWB, functional well-being; MAE, mean abso-
n square error.plas
FACT
uare
cient
02526
02439
00274
00100
00076
00024
82992
.56%
.10%
.70%
18
89
087
067
ia; BI
f Can
t meainformation criteria among prediction models. RMSE and MAE
Table 4 – Prediction models for patients with colorectal neoplasm using main effects, squared terms, interaction terms of FACT-C, and clinical and demographical
variables.
FACT-C–based model
Main effects (C1) Squared terms added (C2) Interaction terms added (C3) Clinical and demographical
variables added (C4)
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
PWB 0.01651* (0.01343,0.01959) 0.02731* (0.04456,0.01007) 0.02091* (0.03820,0.00362) 0.02318* (0.04040,0.00595)
EWB 0.00352* (0.00022,0.00682) 0.02741* (0.05411,0.00071) 0.03780* (0.05613,0.01947) 0.03530* (0.05361,0.01699)
FWB 0.01028* (0.00810,0.01338) 0.01025* (0.00814,0.01237) 0.01442* (0.00080,0.02804) 0.01455* (0.00105,0.02805)
CCS 0.00479* (0.00174,0.00784) 0.00379* (0.00081,0.00676) 0.01911* (0.03516,0.00306) 0.01709* (0.03307,0.00111)
PWB2 0.00101* (0.00063,0.00140) 0.00059* (0.00016,0.00103) 0.00065* (0.00022,0.00109)
EWB2 0.00082* (0.00011,0.00152)
PWB  FWB 0.00076* (0.00025,0.00126) 0.00067* (0.00016,0.00117)
EWB  CCS 0.00200* (0.00112,0.00289) 0.00185* (0.00096,0.00273)
FWB  CCS 0.00104* (0.00158,0.00049) 0.00095* (0.00149,0.00040)
Stage†
Low risk 0.03731* (0.01040,0.06421)
High risk 0.00896 (0.01937,0.03729)
Stage I 0.02641 (0.00091,0.05373)
Stage II 0.03581* (0.00963,0.06198)
Stage III 0.02348 (0.00193,0.04889)
Female 0.01921* (0.03451,0.00391)
Constant 0.02703* (0.04405,0.09812) 0.77787* (0.49933,1.05641) 1.03518* (0.72557,1.34479) 1.01899* (0.71030,1.32767)
R2 55.74% 58.67% 60.43% 61.65%
Adj R2 55.41% 58.20% 59.83% 60.63%
Pred R2 54.31% 56.81% 58.07% 58.41%
AIC 1048.81 1081.50 1100.90 1105.78
BIC 1023.09 1047.22 1058.04 1037.21
RMSE 0.090 0.087 0.085 0.084
MAE 0.069 0.067 0.065 0.065
AE  0.05 302 (56.24%) 273 (50.84%) 263 (48.98%) 263 (48.98%)
AE  0.10 123 (22.91%) 117 (21.79%) 118 (21.97%) 121 (22.53%)
Range of fitted 0.310–0.996 0.459–1.012 0.468–1.005 0.462–1.022
Adj R2, adjusted R2; AE, absolute error; AIC, Akaike information criteria; BIC, Bayesian information criteria; CCS, colorectal cancer subscale; CI, confidence interval; EWB, emotional well-being; fitted,
fitted values; FACT-C, Functional Assessment of Cancer Therapy-Colorectal; FWB, functional well-being; MAE, mean absolute error; Pred R2, predicted R2; PWB, physical well-being; RMSE, root mean
square error.
* Significant with P  0.05.
† Stage IV is the reference category of colorectal neoplasm staging.
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500 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 3were 0.084 and 0.065, respectively, which were better than for
the FACT-G– based model. The percentage of AE greater than
0.05 was 48.98% while that of AE greater than 0.10 was 22.53%.
The fitted values of SF-6D ranged from 0.462 to 1.022, the lower
bound of which was 0.077 more than that of the observed range
(0.385–1). The scatter plot of observed and predicted SF-6D pref-
erence-based values by FACT-C– based mapping function is also
shown in Figure 1. A similar pattern of overprediction is ob-
erved for SF-6D values lower than 0.8, as demonstrated in
able 5. The mapping function of SF-6D using four scores of the
ACT-C subscale (model C3) produced acceptable model perfor-
ance with less than 50% of subjects with AE greater than 0.05
nd the smallest Bayesian information criteria.
Model validation
Table 6 shows the prediction errors in the 10-fold cross-validation
procedure. The RMSE and MAE were estimated to be 0.089 to 0.092
and 0.069 to 0.071, respectively, in FACT-G–based models and
0.088 to 0.091 and 0.068 to 0.070, respectively, in FACT-C–based
models. The percentage of AE greater than 0.05 was between
50.28% and 56.04% while that of AE greater than 0.10 was between
23.07% and 24.02%. Mean SF-6D values predicted by FACT-G/
FACT-C based on cross-validation were 0.825, which were consis-
tent with the actual SF-6D values. Validation results of applying
our mapping functions to patients with CRN suggested that both
models predicted SF-6D preference-based values accurately.
Discussion
Mapping functions have been previously developed by using data
from patients with general cancer [31, 32], esophageal cancer [33],
gastric cancer [15], and prostate cancer [20]. This study is the first
ttempt, to our knowledge, to develop a mapping function to esti-
ate SF-6D preference-based values from condition-specific mea-
ures for patients with CRN. The results from a relatively large
ample of 537 patients with different disease severity confirmed
Fig. 1 – The scatter plot of mean observed and predicted SF-
descending order of the mean observed values.hat SF-6D preference-based values can be estimated from FACT-/FACT-C subscale scores by using mapping functions. A 10-fold
ross-validation was performed to strengthen their validity and
obustness. Our findings suggested that the mapping of a more
pecific measure (FACT-C) had better performance than that of the
eneral cancer measure (FACT-G), probably because it has the ad-
itional scale that captures the HRQOL domain specific to our CRN
atient sample. Final models adding significant square terms, in-
eraction terms of the subscales, and tumor stage and demo-
raphic variables into the main-effect models had slight improve-
ents in the model performance (about 3%–6% increment in R2,
dj R2, and Pred R2) at the expense of model complexity. Simpler
models are sufficient to predict SF-6D preference-based values
with little loss in model performance if demographic and tumor
stage data are not available.
Predictive performances of the preferred models of FACT-G/
FACT-C were good using statistical criteria and standards
achieved by previous mapping studies. A review of mapping stud-
ies [17] found that only 4 of 30 models that reviewed mapping a
condition-specific measure to a generic health preference-based
measure achieved an R2 of 60%. The R2 value of our final FACT-G–
based model was approximately 60%, and the R2 of two of our
FACT-C–based models exceeded 60%. On the whole, the R2, Adj R2,
and Pred R2 of all models were greater than 50%, which repre-
sented acceptable explanatory power. The predictive performance
of the models was also supported by the small proportion (0.10)
of predictions with MAE and RMSE, and for each model less than a
quarter of the sample had an AE of more than 0.10. Table 5 shows
the mean error, RMSE, and MAE of predicted compared with actual
preference-based values by SF-6D range for FACT-G/FACT-C–
based prediction models. When comparing the ranges of the fitted
values of both mapping functions to the observed range of SF-6D
values, a tendency of overprediction was observed in each model
for observed value of SF-6D less than 0.8 (Table 5). The size of mean
error in this article varied across the SF-6D range, with larger er-
rors when the SF-6D value was below 0.8. The mean errors in that
range were larger than 0.03, which was the proposed minimally
important difference for SF-6D scores [34]. Overprediction of low
reference-based values by the health state ranking in6D ppreference-based values also occurred in the literature mapping
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501V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 3onto a variety of preference-based measures including the EQ-5D
questionnaire [21,35,36].
A recent literature review [17] found that MAE reached 0.19,
epresenting around 15% of the possible range of the preference-
ased measure. This problem has been commonly found in the
se of mapping function to estimate preference-based values
ather than measuring a preference-based measure directly in the
tudy of interest. It is important that the uncertainty around the
apped estimates should be taken into account in the cost-effec-
iveness model and research is ongoing in this area.
Several previous studies developed the mapping functions
rom a condition-specific measure onto the EQ-5D questionnaire
reference-based measure by censored least absolute deviations
CLAD), tobit, and standard two-part regressions [32,37–40] be-
ause the EQ-5D questionnaire suffers from high ceiling effects.
ow ceiling effect observed from our SF-6D data, however, did not
upport the use of these models. A study by Cheung et al. [32] that
mapped FACT-G onto preference-based values measured by the
Table 5 – Mean error, RMSE, and MAE of predicted compar
for FACT-G– and FACT-C–based prediction models.
FACT-G–based model
G1 G2
Mean error
0.385–0.500 (n  4) 0.110 0.132 
0.501–0.600 (n  51) 0.090 0.093 
0.601–0.700 (n  61) 0.105 0.089 
0.701–0.800 (n  65) 0.049 0.037 
0.801–0.900 (n  137) 0.010 0.015
0.901–1.000 (n  219) 0.060 0.051
Whole range (n  537) 0.000 0.000
RMSE
0.385–0.500 (n  4) 0.144 0.145
0.501–0.600 (n  51) 0.143 0.125
0.601–0.700 (n  61) 0.131 0.116
0.701–0.800 (n  65) 0.085 0.088
0.801–0.900 (n  137) 0.053 0.064
0.901–1.000 (n  219) 0.081 0.078
Whole range (n  537) 0.091 0.087
MAE
0.385–0.500 (n  4) 0.110 0.132
0.501–0.600 (n  51) 0.119 0.100
0.601–0.700 (n  61) 0.119 0.100
0.701–0.800 (n  65) 0.070 0.073
0.801–0.900 (n  137) 0.037 0.046
0.901–1.000 (n  219) 0.065 0.062
Whole range (n  537) 0.070 0.067
FACT-C, Functional Assessment of Cancer Therapy-Colorectal; FACT
lute error; RMSE, root mean square error; SF-6D, six-dimensional hea
Table 6 – RMSE and MAE for FACT-G– and FACT-C–based p
procedure.
FACT-G–based model
G1 G2 G3
RMSE 0.092 0.089 0.089
MAE 0.071 0.069 0.069
AE  0.05 301 (56.04%) 290 (54.00%) 286 (53.26%)
AE  0.10 129 (24.02%) 124 (23.08%) 127 (23.64%)
AE, absolute error; FACT-C, Functional Assessment of Cancer Therap
RMSE, root mean square error; MAE, mean absolute error.EQ-5D questionnaire achieved a model with R2 of 45.0%, which
was lower than the R2 in our FACT-G–based mapping functions. In
accordance with Cheung et al. [32], the PWB, EWB, and FWB but
not SWB subscale scores were the significant variables in our re-
gression models of FACT-G–based mapping functions. Our map-
ping functions had better predictive performance than did the
models estimated by Cheung et al. [32], which could be due to a
more homogenous patient population and within-sample testing
in our study. Another reason for a higher explanation perfor-
mance of our models was the inclusion of clinical and demo-
graphic variables that were not included in their models. Further-
more, the ceiling effects of SF-6D are lower than those of the EQ-5D
Questionnaire, which could also lead to a difference in the perfor-
mance of the mapping functions [41].
Although the ordinary least square regression is the most com-
mon mapping approach [17], it is limited to the normality and
homoscedasticity assumptions for residuals. Because of the ceil-
ing effect of the SF-6D preference-based measure, a small extent
ith actual SF-6D preference-based values by SF-6D range
FACT-C–based model
C1 C2 C3 C4
9 0.113 0.115 0.119 0.115
3 0.089 0.092 0.086 0.087
3 0.104 0.091 0.089 0.083
4 0.046 0.038 0.037 0.034
3 0.012 0.014 0.014 0.013
9 0.058 0.051 0.049 0.048
0 0.000 0.000 0.000 0.000
7 0.137 0.135 0.127 0.125
5 0.143 0.129 0.127 0.128
1 0.132 0.120 0.118 0.112
6 0.084 0.087 0.086 0.084
3 0.053 0.061 0.061 0.061
7 0.078 0.076 0.073 0.073
6 0.090 0.087 0.085 0.084
9 0.113 0.115 0.119 0.115
2 0.118 0.104 0.098 0.101
5 0.119 0.104 0.102 0.097
0 0.069 0.072 0.071 0.068
6 0.038 0.044 0.045 0.045
1 0.063 0.059 0.058 0.057
7 0.069 0.067 0.065 0.065
nctional Assessment of Cancer Therapy-General; MAE, mean abso-
tate short form (derived from short form 36 health survey).
ction models following 10-fold cross-validation
FACT-C–based model
C1 C2 C3 C4
0.091 0.089 0.088 0.088
0.070 0.068 0.068 0.068
00 (55.87%) 274 (51.00%) 270 (50.28%) 277 (51.58%)
26 (23.45%) 124 (23.08%) 124 (23.07%) 128 (23.82%)
orectal; FACT-G, Functional Assessment of Cancer Therapy-General;ed w
G3
0.12
0.09
0.08
0.03
0.01
0.04
0.00
0.13
0.12
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502 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 9 5 – 5 0 3of violation of the normality and homoscedasticity assumptions
was indicated by the residual plots of the regression models,
which might have caused some biases in our coefficient estimates.
Alternative mapping methods such as response mapping [42] and
probabilistic mapping [43] have been used to map the Short Form
12-Item (SF-12) onto EQ-5D Questionnaire responses by others.
Each EQ-5D Questionnaire dimension is classified into three re-
sponse levels to allow sufficient amount of subjects for model de-
velopment. However, our SF-6D data fitted poorly to these models
because only a few subjects reported the worst response level in
the SF-6D dimensions: physical functioning (3, 0.5%), pain (4,
0.7%), mental health (1, 0.2%), and vitality (8, 1.5%).
Limitations
Our results from Chinese patients with CRN may not be applicable to
non-Chinese populations, not least because the SF-6D values pre-
dicted by the models are based on Hong Kong preferences weights.
Furthermore, our models were developed for a homogeneous CRN
patient population, which may not be generalizable to other cancer
patient groups. It should be with caution that the model developed in
this study should be validated on another sample before fitting on
other data sets. In addition, the exclusion of ill patients might be the
reason for the high ceiling effect observed on the PWB subscale, lead-
ing to high mean SF-6D values of 0.825. This might also be explained
that most of the patients were long-term survivors with diagnosis of
neoplasms for more than 6 months.
Conclusions
Mapping of FACT-G/FACT-C subscale scores onto SF-6D preference-
based values reached an acceptable degree of precision for Chinese
patients with CRN. The best models for the estimation of SF-6D pref-
erence-based value included the FACT-G/FACT-C subscale scores,
sex, and tumor stage. These mapping functions can be applied to
FACT-G/FACT-C data sets to predict SF-6D utility values for use in
cost-effectiveness analysis of medical interventions for patients with
CRN. Further studies on non-Chinese populations and different can-
cer patient groups are needed to validate the applicability of our
mapping functions before wider applications.
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